• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Agape ATP Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    3/12/26 9:00:25 AM ET
    $ATPC
    Medical/Nursing Services
    Health Care
    Get the next $ATPC alert in real time by email
    false 0001713210 0001713210 2026-03-12 2026-03-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 12, 2026 (March 10, 2026)

     

    AGAPE ATP CORPORATION

    (Exact name of Registrant as specified in its charter)

     

    Nevada   001-41835   36-4838886
    (State or other jurisdiction   (Commission   (IRS Employer
    of incorporation)   File Number)   Identification No.)

     

    1705 – 1708, Level 17, Tower 2, Faber Towers, Jalan Desa Bahagia,

    Taman Desa, Kuala Lumpur, Malaysia (Postal Code: 58100).

    (Address of principal executive offices, including zip code)

     

    Registrant’s phone number, including area code

    +(60) 192230099

     

    N/A

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

      ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
         
      ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
         
      ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
         
      ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001   ATPC   NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17CFR §240.12b-2).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    As previously announced, the Company received a letter (the “Notification Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) on January 27, 2026, notifying the Company that, based upon the closing bid price of the Company’s ordinary shares for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”), which matter serves as a basis for delisting the Company’s securities from Nasdaq. On February 2, 2026, the Company received an additional Notification Letter notifying the Company that the Staff has determined to delist the Company’s securities. The Staff’s determination was based on that as of January 30, 2026, the Company’s securities had a closing bid of $0.10 or less for the last ten consecutive trading days, and accordingly, is subject to the provisions under Listing Rule 5810(c)(3)(A)(iii), the “Low Priced Stocks” Rule.

     

    On March 10, 2026, the Company received a letter from the Hearings Advisor of Nasdaq, noting that the Nasdaq Listing Qualifications staff have advised the Hearings Department that the Company has regained compliance with the bid price requirement in Listing Rule 5550(a)(2) and that the Company is therefore in compliance with the Nasdaq Capital Market’s listing requirements. Consequently, the hearing before the Hearings Panel scheduled to take place on March 17, 2026 has been cancelled. The Company’s Common stock will continue to be listed and traded on The Nasdaq Stock Market.

     

    On March 12, 2026, the Company issued a press release announcing the letter from the Hearings Advisor of Nasdaq. The full text of the Press Release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

     

    Exhibit Index

     

    Exhibit No.   Description
    99.1*   Press Release dated March 12, 2026
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: March 12, 2026 AGAPE ATP CORPORATION
         
      By: /s/ How Kok Choong
      Name: How Kok Choong
      Title: Chief Executive Officer, President, Director, Secretary and Treasurer (Principal Executive Officer)

     

    3

     

    Get the next $ATPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATPC
    SEC Filings

    View All

    SEC Form NT 10-K filed by Agape ATP Corporation

    NT 10-K - Agape ATP Corp (0001713210) (Filer)

    3/31/26 4:20:28 PM ET
    $ATPC
    Medical/Nursing Services
    Health Care

    Agape ATP Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Agape ATP Corp (0001713210) (Filer)

    3/12/26 9:00:25 AM ET
    $ATPC
    Medical/Nursing Services
    Health Care

    Agape ATP Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Agape ATP Corp (0001713210) (Filer)

    3/10/26 9:00:39 AM ET
    $ATPC
    Medical/Nursing Services
    Health Care

    $ATPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ATPC Expands Global Market Footprint to Spearhead Medical Innovation with MoUs in Indonesia

    Agreements to drive clinical research, enhance product safety, and combat respiratory diseases KUALA LUMPUR, MALAYSIA / ACCESSWIRE / November 29, 2024 / NASDAQ-listed AGAPE ATP Corporation ("ATPC"), today announced the signing of three Memorandums of Understanding ("MOUs") with prominent healthcare institutions in Indonesia. This initiative aims to advance medical research, introduce innovative treatment strategies and strengthen training programs to address respiratory diseases such as tuberculosis (TB) and chronic obstructive pulmonary disease (COPD). The signing marks a key milestone in ATPC's strategic expansion plans in Indonesia and Southeast Asia.(L-R): Dr. Fernando Cortizo, ED, Prof.

    11/29/24 9:00:00 AM ET
    $ATPC
    Medical/Nursing Services
    Health Care

    Agape ATP Corporation - Synergising Innovation Across Business Pillars to Make the World a Better Place

    ATPC Unveils Its Multifaceted Business Pillars to Drive Global Wellness and Sustainability KUALA LUMPUR, MALAYSIA / ACCESSWIRE / October 10, 2024 / NASDAQ-listed AGAPE ATP Corporation ("ATPC"), is proud to present its multifaceted business pillars, each driven by a shared vision to make the world a better place. With a strong commitment to sustainability, health, and enhancing quality of life, ATPC has strategically developed six (6) core pillars that work in synergy to address the world's most pressing challenges, from energy conservation to advanced medical care.ATPC Green Energy ("AGE") spearheads ATPC's efforts in the energy sector, with initiatives aiming to provide sustainable energy s

    10/10/24 9:20:00 AM ET
    $ATPC
    Medical/Nursing Services
    Health Care

    ATPC and FORMEDIC Technologies Announce Strategic Collaboration to Launch LEGA, a Revolutionary Respiratory Care Device

    Innovative Collaboration Brings Advanced Respiratory Solutions to a Global Market KUALA LUMPUR, MALAYSIA / ACCESSWIRE / September 30, 2024 / NASDAQ-listed AGAPE ATP Corporation ("ATPC"), is proud to announce a strategic collaboration with FORMEDIC Technologies Sdn. Bhd. ("FORMEDIC Technologies") to introduce LEGA, an electronic chest percussion device for respiratory care. This partnership marks a major advancement in respiratory health, as the two companies combine their strengths to address the growing demand for advanced respiratory solutions.LEGA, FORMEDIC's flagship product, assists patients with chronic obstructive pulmonary diseases ("COPD"), pneumonia, bronchiectasis, and other lung-

    9/30/24 11:45:00 PM ET
    $ATPC
    Medical/Nursing Services
    Health Care

    $ATPC
    Leadership Updates

    Live Leadership Updates

    View All

    Agape ATP Corporation Announces US$1 Million Share Repurchase Plan

    KUALA LUMPUR, MALAYSIA / ACCESSWIRE / November 22, 2023 / AGAPE ATP Corporation (NASDAQ:ATPC) ("ATPC" or the "Company") announced that its board of directors has authorized a share repurchase plan under which the Company may repurchase up to US$1 million of its shares over the next 6 months. The board of directors have also approved the appointment of Network 1 Financial Securities as the broker to execute the repurchase on behalf of ATPC.The share repurchases may be made from time to time in the open market transactions, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable secur

    11/22/23 9:00:00 AM ET
    $ATPC
    Medical/Nursing Services
    Health Care